UAE's multiple myeloma therapeutics market was valued at $42 Mn in 2022 and is estimated to expand at a CAGR of 5.5% from 2022 to 2030 and will reach $64 Mn in 2030. One of the main reasons propelling the growth of this Market is the growing demand for innovative therapies and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Julphar, Neopharma, Medpharma, LifePharma, Gulf Pharmaceutical, Pharmax Pharmaceuticals, and others.
UAE's multiple myeloma therapeutics market was valued at $42 Mn in 2022 and is estimated to expand at a CAGR of 5.5% from 2022 to 2030 and will reach $64 Mn in 2030. A disease, sickness, or damage is diagnosed based on a patient's signs and symptoms, as well as the patient's health history and physical exam. Following a clinical diagnosis, additional testing may be undertaken, such as blood tests, imaging investigations, and biopsies. The immunoassay segment is the largest and fastest-growing segment in the clinical diagnostics Market in UAE, accounting for more than 50% of the Market share. The growth of this segment is driven by the increasing demand for rapid diagnostic tests for infectious diseases and the rising adoption of point-of-care testing.
Moreover, the Chinese government is implementing various initiatives to boost the growth of the clinical diagnostics Market in the country, such as the 13th Five-Year Plan for Health and Family Planning (2016-2020), which focuses on the development of advanced medical devices and technologies, including clinical diagnostics.
Market Growth Drivers
Multiple myeloma has become increasingly prevalent in the UAE due to a growing aging population and lifestyle changes, such as sedentary behavior and unhealthy diets. Greater awareness of multiple myeloma and the availability of screening tests are helping to diagnose the disease at earlier stages, potentially leading to better outcomes and increased demand for treatment options. The UAE government has invested heavily in expanding its healthcare infrastructure, including hospitals and clinics, which can lead to increased access to multiple myeloma treatment. The UAE population is becoming more affluent, and patients are increasingly willing to pay for innovative therapies and personalized medicine options.
The healthcare infrastructure in the UAE is still developing, and this could impact the availability of treatment options for multiple myeloma patients. While the UAE has made significant strides in developing its healthcare infrastructure, the availability of advanced therapies for multiple myeloma treatment remains limited. The cost of multiple myeloma treatment in the UAE can be prohibitively high for many patients, which could lead to limited access to treatment. There is still limited awareness among the general population about multiple myeloma, its symptoms, and treatment options. The availability of data on multiple myeloma in the UAE is limited, which could impact the ability to develop effective treatment strategies. The ongoing conflicts in the region, including the Yemeni conflict, could have an impact on the availability of healthcare resources, including those needed for multiple myeloma treatment.
The healthcare policy and regulatory framework in the UAE (United Arab Emirates) is overseen by the Ministry of Health and Prevention (MOHAP) and the Dubai Health Authority (DHA). The UAE has a well-developed healthcare system that is constantly improving, and the government has made significant investments in the sector to ensure that patients receive high-quality care.
In terms of the regulatory framework, the UAE has a rigorous drug registration process, which ensures that all drugs sold in the country meet strict safety and efficacy standards. The MOHAP oversees the registration process for pharmaceuticals, and all drugs must be approved by the MOHAP before they can be marketed in the country. The UAE also has a system in place to monitor drug safety and adverse events, which helps to ensure that patients are protected
In addition, the UAE has a universal healthcare system, which provides citizens and residents with access to healthcare services. The government has also taken steps to encourage private investment in the healthcare sector, which has led to the development of private hospitals and clinics.
The healthcare system in UAE is mainly public-funded, and the government provides free or subsidized healthcare services to its citizens. In the UAE, the government and private health insurance providers are responsible for reimbursing patients for their medical expenses.
For cancer treatment, the Dubai Health Authority (DHA) provides a program called the "Thiqa" plan, which covers the full cost of cancer treatment for eligible UAE nationals. Non-nationals can access healthcare services through their insurance coverage, and the reimbursement amount depends on the specific policy they have.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
22.214.171.124 Product Applications and Services
126.96.36.199 Recent Developments
188.8.131.52 Partnerships Ecosystem
184.108.40.206 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Distribution Channel
By End User (Revenue, USD Bn):
By Drug Class
Immunomodulatory drugs (IMiDs)
One of the most common therapies used to treat myeloma is immunomodulatory drugs or IMiDs. These drugs work by modifying the immune system to attack myeloma cells and have been a significant advance in the treatment of multiple myeloma. Some of the commonly used IMiDs in multiple myeloma include:
Proteasome inhibitors are a class of drugs that are commonly used in the treatment of multiple myeloma. They work by blocking the activity of proteasomes, which are cellular structures that break down proteins. This leads to the accumulation of proteins within the myeloma cells, ultimately causing their death. Some proteasome inhibitors used in multiple myeloma include:
Monoclonal antibodies, target specific proteins on the surface of myeloma cells, causing them to be destroyed by the immune system. Some of the commonly used monoclonal antibodies in multiple myeloma include:
Chemotherapy drugs work by killing rapidly dividing cells, including cancer cells. Chemotherapy is often used in combination with other drugs, such as steroids, immunomodulatory drugs, or proteasome inhibitors, to improve their effectiveness. Here are some chemotherapy drugs used in multiple myeloma:
Steroids such as dexamethasone and prednisone are often used in combination with other drugs to treat multiple myeloma. They can reduce inflammation, suppress the immune system, and promote the death of myeloma cells.
Steroids are effective in reducing inflammation and suppressing the immune system, which can help to control the growth of myeloma cells. However, they can have side effects, such as weight gain, mood changes, and increased risk of infection, so their use needs to be carefully monitored.
Other drug classes used to treat multiple myeloma include:
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses